Skip to main content

Table 3 Dose–volume histogram results for OARs

From: Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer

OARs

Range

Mean ± SD

Bladder

Volume

81.2–477.8

231.8 ± 131.8

Dmax

72.20–75.00

73.51 ± 0.70

Dmean

6.61–38.86

20.81 ± 9.57

Dmedian

0.16–39.69

10.85 ± 11.91

BV73Gy

0–4.0

0.74 ± 1.12

BV72Gy

0.03–11.37

4.14 ± 3.37

BV70Gy

0.61–17.78

7.85 ± 5.51

BV68.4 Gy

0.89–20.69

9.34 ± 6.36

BV65Gy

1.53–24.83

11.87 ± 7.38

BV60Gy

2.50–29.69

15.07 ± 8.78

BV55Gy

3.48–36.65

18.05 ± 10.13

BV50Gy

4.67–40.65

20.62 ± 11.03

BV40Gy

6.73–49.67

25.45 ± 12.83

BV30Gy

9.15–58.30

30.24 ± 14.43

BV20Gy

11.95–67.98

35.79 ± 16.31

BV10Gy

16.12–80.30

43.49 ± 18.61

Rectum

Volume

135.2–231.1

179.3 ± 27.0

Dmax

71.02–76.00

73.49 ± .99

Dmean

9.73–36.39

20.84 ± 6.14

Dmedian

1.60–38.41

9.50 ± 8.34

RV73Gy

0.00–1.53

0.31 ± 0.43

RV72Gy

0.00–6.66

1.94 ± 1.69

RV70Gy

0.05–10.72

4.64 ± 3.28

RV68.4 Gy

0.15–12.64

6.03 ± 3.89

RV66Gy

0.37–15.83

7.85 ± 4.70

RV65Gy

0.51–17.69

8.56 ± 5.0

RV62Gy

1.05—23.25

10.68 ± 5.92

RV60Gy

1.82–26.75

12.14 ± 6.29

RV55Gy

3.12–33.46

15.90 ± 7.03

RV50Gy

4.57–38.92

19.16 ± 7.71

RV40Gy

8.26–48.65

24.87 ± 8.97

RV30Gy

12.61–56.85

30.54 ± 9.96

RV20Gy

18.25–64.97

37.01 ± 10.83

RV10Gy

26.67–74.97

46.13 ± 11.63

Femoral head

Right Dmax

30.60–47.60

34.3 ± 4.28

Right Dmean

17.26–31.26

26.73 ± 3.5

Left Dmax

30.60–50.00

34.38 ± 4.16

Left Dmean

18.14–31.35

27.02 ± 3.59

Penile bulb

Dmean

2.96–61.43

23.18 ± 19.32

  1. *Dose in Gy; BVXGy = Percentage of bladder volume received X dose; RVXGy = Percentage of rectal volume received X dose